Phase 1 N=17 Boceprevir and Ucalm (St John&Apos;s Wort)
Hepatitis C
Primary: Pharmacokinetic of Boceprevir in the Presence of Ucalm (St John's Wort) — 4588; 4204; 11.6; 14.3 ng*h/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=48 Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities
Leukemia, Myeloid, Acute
Primary: Complete Remission Rate (CRm + CRi + CRc) — 0; 3; 0; 4 participants
Phase 4 N=25 Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
Type 1 Diabetes Mellitus
Primary: Early Insulin Exposure (%AUC[0-60]) — 33.53; 17.85; 39.45; 33.52 percentage of AUC(0-60) — p=<0.0001
Phase 4 N=479 Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
Myocardial Infarction
Primary: Device-oriented Composite Outcome — 12; 13 participants
Phase 2 N=211 Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d. — 71.1; 84.2; 78.0; 19.0 Percentage of participants — p=<0.001
Phase 1 N=9 Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules
Pulmonary Nodule
Primary: Feasibility of Ultra Short-term Steroid Therapy to Increase the Accuracy of FDG-PET/CT Imaging — 3.97; 4.27 gm/ml
Phase 1 N=19 A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers
HIV
Primary: Maximum Observed Concentration (Cmax) of Raltegravir and Amlodipine Without and With Co-administration of the Other Studied Drug. — 1178; 1866; 8.47; 8.49 ng/mL
Phase 2 N=56 Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Determination of the Maximum Tolerated Dose (MTD) of Dasatinib When Given in Combination With Ixabepilone (Phase I) — 100 mg daily
Phase 2 N=210 Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
Neoplasms · Breast Neoplasms · Breast Cancer
Primary: Phase I: The Number of Dose Limiting Toxicities in AZD8931 in Combination With Weekly Paclitaxel — 2; 1; 2; 0 Number of Dose Limiting Toxicities
Phase 4 N=81 Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: A Change in Abdominal Pain Severity — 259.66; 256.04; 199.13; 201.98 units on a scale — p=<0.05
Phase 1 N=31 Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)
Chronic Hepatitis C
Primary: Number of Participants From Whom Detectable Concentrations of Hepatic Vaniprevir Are Obtained by FNA — 10; 9; 10 Participants
Phase 2 N=9 CC-10004 For The Treatment Of Vulvodynia
Vulvodynia
Primary: Global Response Assessment — 5 participants
N/A N=10 Acupressure and Acupuncture as an Intervention With Children With Autism II
Autism Spectrum Disorder
Primary: Proportions of Children Completing Acupressure and Acupuncture Treatment. — 9 participants
N/A N=73 Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
HIV
Primary: Effect of CYP2B6 Genotype on Efavirenz Clearance — 93.35; 76.08; 51.03; 50.05 ml/h/kg
Phase 2 N=1 Vismodegib for Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Mohs Micrographic Surgery (MMS) — 1 mm